Comparing efficacy and safety of fibrinogen concentrate to cryoprecipitate in bleeding patients: a systematic review

Acta Anaesthesiologica Scandinavica

Volumn 60, Issue 8, 2016, Pages 1033-1042

  Jensen, N H L ^a   Stensballe, J ^b   Afshari, A ^b  

^a BISPEBJERG HOSPITAL   (Denmark)

^b University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; FIBRINOGEN CONCENTRATE;

BLEEDING; BLEEDING DISORDER; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CRYOPRECIPITATE; ERYTHROCYTE TRANSFUSION; FIBRINOGEN BLOOD LEVEL; HEMOSTASIS; HUMAN; META ANALYSIS (TOPIC); OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW;

EID: 84980459442     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/aas.12734     Document Type: Review

References (48)

1. Stokes ME, Ye X, Shah M, Mercaldi K, Reynolds MW, Rupnow MF, Hammond J. Impact of bleeding product transfusions on hospital costs in inpatient surgical patients. BMC Health Sci 2011; 11: 135–48.
2. Galas FRBG, Almeida JP, Fukuchima JT, Osawa EA, Nakamura RE, Silva CM, de Almeida EP, Auler JO, Vincent JL, Hajjar LA. Blood transfusion in cardiac surgery is a risk factor for increased hospital length of stay in adult patients. J Card Surg 2013; 8: 54–61.
3. Holcomb JB, Fox EE, Zhang X, White N, Wade CE, Cotton BA, Del JD, Bulger ECM, Schreiber MA, Myers JG, Brasel KJ, Phelan HA, Alarcon LH, Muskat P, Rahbar MH. Cryoprecipitate use in the Prospective Observational Multicenter Major Trauma Transfusion Study (PROMMTT). J Trauma Acute Care Surg 2013;75:S31–9.
4. Johansson PI, Stensballe J, Oliveri R, Wade CE, Ostrowski ST, Holcomb JB. How I treat patients with massive haemorrhage. Blood 2014; 124: 3052–8.
5. Charbit B, Mandelbrot L, Samain E, Baron G, Haddaoui B, Keita H, Sibony O, Mahieu-Caputo D, Hurtaud-Roux MF, Huisse MG, Denninger MH, de Prost D, PPH Study Group. The decrease of fibrinogen is an early predictor of the severity of postpartum haemorrhage. J Thromb Haemost 2007; 5: 266–73.
6. Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995; 81: 360–5.
7. Fenger-Eriksen C, Lindberg-Larsen M, Christensen AQ, Ingerslev J, Sørensen B. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. Br J Anaesth 2008; 101: 769–73.
8. Mittermayr M, Streif W, Haas T, Fries D, Velik-Salchner C, Klingler A, Oswald E, Bach C, Schnapka-Koeft M, Innerhofer P. Haemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: the Role of Fibrinogen Administration. Anesth Analg 2007; 105: 905–17.
9. Caballo C, Escolar G, Diaz-Ricar M, Lopez-Vilchez I, Lozano M, Cid J, Pino M, Beltran J, Basora M, Pereira A, Galan AM. Impact of experimental haemodilution on platelet function, thrombin generation and clot firmness: effects of different coagulation factor concentrates. Blood Transfus 2013; 11: 391–9.
10. Martini WZ. Fibrinogen metabolic responses to trauma. Scand J Trauma Resusc Emerg Med 2009; 17: 2–8.
11. Sørensen B, Bevan D. A critical evaluation of cryoprecipitate for replacement of fibrinogen. Br J Haematol 2010; 149: 834–43.
12. Lunde J, Stensballe J, Wikkelsø A, Johansen M, Afshari A. Fibrinogen concentrate for bleeding- a systematic review. Acta Anasethesiol Scand 2014; 58: 1061–74.
13. Franchini M, Lippi G. Fibrinogen replacement therapy. Blood Transfus 2012; 10: 23–7.
14. Wikkelsoe AJ, Afshari A, Stensballe J, Langhoff-Roos J, Albrechtsen C, Ekelund K, Hanke G, Sharif HF, Mitchell AU, Svare J, Troelstrup A, Pedersen LM, Lauenborg J, Madsen MG, Bødker B, Møller AM. The FIB-PPH Trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomized controlled trial. Trials 2012; 13: 110–8.
15. Harr JN, Moore EE, Ghasabyan A, Chin TL, Sauaia A, Banerjee A, Silliman CC. Functional fibrinogen assay indicates that fibrinogen is critical in correcting abnormal clot strength following trauma. Shock 2013; 39: 45–9.
16. Meyer MA, Ostrowski SR, Sørensen AM, Meyer AS, Holcomb JB, Wade CE, Johansson PI, Stensballe J. Fibrinogen in trauma, an evaluation of thromboelastography and rotational thromboelastometry fibrinogen assays. J Surg Res 2015; 194: 581–90.
17. Solomon C, Hagl C, Rahe-Meyer N. Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. Br J Anaesth 2013; 110: 947–56.
18. Solomon C, Pichlmaier U, Schoechl IH, Hagl C, Raymondos K, Scheinichen D, Koppert W, Rahe-Meyer N. Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery. Br J Anaesth 2010; 104: 555–62.
19. Rahe-Meyer N, Solomon C, Hanke A, Schmidt DS, Knoerzer D, Hochleitner G, Sørensen B, Hagl C, Pichlmaier M. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery. Anesthesiology 2013; 118: 40–50.
20. Poon MC. Cryoprecipitate: uses and alternatives. Trans Med 1993; 7: 180–92.
21. Hornsey VS, Young DA, Docherty A, Hughes W, Prowse CV. Coagulation factor content of cryoprecipitate prepared from methylene blue plus light virus-inactivated plasma. Br J Haematol 2000; 109: 665–70.
22. Idris SF, Hadjinicolaou AV, Sweeney M, Winthrop C, Balendran G, Besser M. The efficacy and safety of cryoprecipitate in the treatment of acquired hypofibrinogenaemia. Br J Haematol 2014; 166: 449–67.
23. Hutton JL, Williamson PR. Bias in meta-analysis due to outcome variable selection within studies. J R Stat Soc Ser C Appl Stat 2000; 49: 359–70.
24. Egger M, Schneider M, Davey Smith G. Spurious precision? Meta-analysis of observational studies BMJ 1998;316:140–4.
25. Shrier I, Boivin JF, Steele RPR, Furlan A, Kakuma R, Brophy J, Rossignol M. Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles Am J Epidemiol 2007;166:1203–9.
26. McLinnok C, Van der Westhuizen J, Wright J. The effect of Upfront Administration of Fibrinogen Concentrate in Obstetric Haemorrhage - A Pilot Study. 2014 Clinical Trial Protocol. Universal Trial Number U1111-1157-9979.
27. Cui Y, Hei F, Long C, Feng Z, Zhao J, Yan F, Wang Y, Liu J. Perioperative monitoring of thromboelastography of blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artif Organs 2010; 34: 955–60.
28. Karlsson M, Ternstrom L, Hyllner M, Baghaei F, Flinck A, Skrtic S, Jeppsson A. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. J Thromb Haemost 2009; 102: 137–44.
29. Lance MD, Ninivaggi M, Schols SE, Feijge MA, Oehrl SK, Kuiper GJ, Nikiforou M, Marcus MA, Hamulyak K, ten Cate H, Heemskert JWM. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sang 2012; 103: 25–34.
30. Tanaka KA, Egan K, Szlam F, Ogawa S, Roback JD, Sreeram G, Guyton RA, Chen EP. Transfusion and hematologic variable after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lympholized human fibrinogen concentrate vs. conventional transfusion. Transfusion 2013; 54: 109–18.
31. Galas F, de Almeida JP, Fukushima JT, Vincent JL, Osawa EA, Zeferino S, Câmara L, Guimarães VA, Jatene MB, Hajjar LA. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after surgery: a randomised pilot trial. J Thorac Cardiovasc Surg 2014; 148: 1647–55.
32. Yang L, Vuylsteke A, Gerrard C, Besser M, Baglin T. Postoperative fibrinogen level is associated with post operative bleeding following cardiothoracic surgery and the effect of fibrinogen replacement therapy remains uncertain. J Thromb Haemost 2013; 11: 1519–26.
33. Theodoulou A, Berryman J, Nathwani A, Scully M. Comparison of cryoprecipitate with fibrinogen concentrate for acquired hypofibrinogenaemia. Transfus Apher Sci 2012; 45: 159–62.
34. Ahmed S, Harrity C, Johnson S, Varadkar S, McMorrow S, Fanning R, Flynn CM, O' Riordan JM, Byrne BM. The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage-an observational study. Transfus Med 2012;22:344–9.
35. Stensballe J, Ostrowski SR, Johansson PI. Viscoelastic guidance of resuscitation. Curr Opin Anaesthesiol 2014; 27: 212–8.
36. Newell DJ. Intention-to-treat analysis: implications for qualitive and quantitive research. Int J Epidemiol 1992; 21: 837–41.
37. Curry N, Rourke C, Davenport R, Beer S, Pankhurst L, Deary A, Thomas H, Llewelyn C, Green L, Doughty H, Nordmann G, Brohi K, Stanworth S. Early cryoprecipitate for major haemorrhage in trauma: a randomized control feasibility trial. Br J Anaesth 2015;115:76–83.
38. Hazra S, Chilaka VN, Rajendran S, Konje JC. Massive postpartum haemorrhage as a cause of maternal morbidity in a large tertiary hospital. J Obstet Gynaecol 2004; 24: 519–20.
39. Wikkelsø AJ, Edward HM, Afshari A, Stensballe J, Langhoff-Roos J, Albrechtsen C, Ekelund K, Hanke G, Secher EL, Sharif HF, Pedersen LM, Troelstrup A, Lauenborg J, Mitchell AU, Fuhrmann L, Svare J, Madsen MG, Bødker B, Møller AM, FIB-PPH Trial group. Pre-emptive treatment with fibrinogen concentrate for postpartum haemorrhage: randomized controlled trial. Br J Anaesth 2015; 114: 623–33.
40. Pereira A. Cryoprecipitate vs. commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Hematol J 2007; 92: 846–9.
41. Makris M. Is the continued use of UK plasma sourced cryoprecipitate justified? Br J Haematol 2014; 13: 161.
42. Lee SH, Lee SM, Kim CS, Cho HS, Lee JH, Lee CH, Kim E, Sung K, Solomon C, Kang J, Kim YR. Fibrinogen recovery and changes in fibrin-based clot firmness after cryoprecipitate administration in patients undergoing aortic surgery involving deep hypothermic circulatory arrest. Transfusion 2014; 54: 1379–87.
43. Rahe-Meyer N, Pichlmaier M, Haverich A, Solomon C, Winterhalter M, Piepenbrock S, Tanaka KA. Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study. Br J Anaesth 2009; 102: 785–92.
44. Bilecen A, Peelen LM, Kalkman CJ, Spanjersberg AJ, Moons KG, Nierich AP. Fibrinogen concentrate therapy in complex cardiac surgery. J Cardiothorac Vasc Anaesth 2013; 27: 12–7.
45. Velik-Calchner C, Hass T, Innerhofer P, Streif W, Nussbaumer W, Klingler A, Klima G, Martinowitz U, Fries D. The effect of fibrinogen concentrate on thrombocytopenia. J Thromb Haemost 2006; 5: 1019–25.
46. Elliott BM, Aledort LM. Restoring Hemostasis: fibrinogen concentrate vs. cryoprecipitate. Expert Rev Hematol 2013; 6: 277–86.
47. Kozek-Langencker A, Sørensen B, Hess JR, Spahn DR. Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Crit Care Med 2011; 15: R239.
48. Ranucci M, Soloman C. Supplementation of fibrinogen in acquired bleeding disorders: experience, evidence, guidelines, and licences. Br J Anaesth 2012; 109: 135–7.